BR9913026A - Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano - Google Patents

Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano

Info

Publication number
BR9913026A
BR9913026A BR9913026A BR9913026A BR9913026A BR 9913026 A BR9913026 A BR 9913026A BR 9913026 A BR9913026 A BR 9913026A BR 9913026 A BR9913026 A BR 9913026A BR 9913026 A BR9913026 A BR 9913026A
Authority
BR
Brazil
Prior art keywords
vlps
papillomavirus
particles
preparing
human
Prior art date
Application number
BR9913026A
Other languages
English (en)
Inventor
James C Cook
Iii
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9913026A publication Critical patent/BR9913026A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSO DE PURIFICAçãO DE PARTìCULAS SEMELHANTES A VìRUS (VLPS) DE PAPILOMAVìRUS RECOMBINANTE, E, PROCESSO DE PREPARAçãO DE UM PRODUTO DE VLP DE PAPILOMAVìRUS HUMANO PURIFICADO ADEQUADO PARA USO EM UMA VACINA PARA HUMANO". Um processo para purificação de partículas semelhantes a vírus (VLPs) de papilomavírus inclui a etapa de passar uma solução contendo VLP parcialmente purificada através de uma coluna cromatográfica de hidróxi-apatita. As VLPs são então eluídas utilizando um tampão contendo ânion fosfato. As vantagens deste processo incluem a recuperação de um elevado rendimento de VLPs intactas.
BR9913026A 1998-08-14 1999-08-10 Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano BR9913026A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9656898P 1998-08-14 1998-08-14
PCT/US1999/017930 WO2000009671A1 (en) 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles

Publications (1)

Publication Number Publication Date
BR9913026A true BR9913026A (pt) 2001-09-25

Family

ID=22257989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913026A BR9913026A (pt) 1998-08-14 1999-08-10 Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano

Country Status (24)

Country Link
US (1) US6602697B1 (pt)
EP (1) EP1105466B1 (pt)
JP (1) JP4440471B2 (pt)
KR (1) KR20010072470A (pt)
CN (1) CN1354787A (pt)
AT (1) ATE324436T1 (pt)
AU (1) AU760633B2 (pt)
BR (1) BR9913026A (pt)
CA (1) CA2339034C (pt)
CY (1) CY1105084T1 (pt)
CZ (1) CZ2001570A3 (pt)
DE (1) DE69931053T2 (pt)
DK (1) DK1105466T3 (pt)
EA (1) EA200100236A1 (pt)
ES (1) ES2262333T3 (pt)
HR (1) HRP20010113A2 (pt)
HU (1) HUP0103091A3 (pt)
IL (1) IL141130A0 (pt)
NZ (1) NZ509610A (pt)
PL (1) PL347472A1 (pt)
PT (1) PT1105466E (pt)
SI (1) SI1105466T1 (pt)
SK (1) SK2232001A3 (pt)
WO (1) WO2000009671A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266604A3 (en) * 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
JP2000262280A (ja) * 1999-03-18 2000-09-26 Asahi Optical Co Ltd ウィルスまたはウィルス性抗原の精製方法およびワクチンの製造方法
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
US7479222B2 (en) * 2004-02-05 2009-01-20 Millipore Corporation Porous adsorptive or chromatographic media
CA2560487C (en) * 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
AU2005280896B2 (en) 2004-09-10 2010-08-05 Asahi Glass Company, Limited Vaccine for oral administration
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
US20100288029A1 (en) * 2006-08-30 2010-11-18 Ge Healthcar Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
ATE496935T1 (de) * 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
WO2008145021A1 (en) * 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) * 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
EP2011573B1 (en) * 2007-11-05 2010-07-21 Agilent Technologies, Inc. Freezing a microfluidic chip
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP3382011A1 (en) 2008-08-08 2018-10-03 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
CA2787009C (en) 2010-01-15 2018-04-03 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
CA2825651C (en) 2011-02-02 2020-03-24 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
PL3299030T3 (pl) 2011-07-11 2022-12-05 Takeda Vaccines, Inc. Pozajelitowe preparaty szczepionek przeciw norowirusowi
MX355352B (es) 2011-12-01 2018-04-17 Univ Cape Town Particulas quimericas de vph.
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
CN105392569B (zh) 2014-06-23 2019-08-20 生物辐射实验室股份有限公司 磷灰石预处理
US10092857B2 (en) 2014-06-23 2018-10-09 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN108524929B (zh) * 2017-03-06 2019-05-07 广州瑞贝斯药业有限公司 一种狂犬病疫苗的生产方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6078999A (ja) 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
SE9000650L (sv) 1989-02-28 1990-08-29 Asahi Optical Co Ltd Separation av celler eller virus
CA2189882C (en) * 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
CA2200582C (en) * 1994-09-22 2007-03-27 Merck & Co., Inc. Dna encoding human papillomavirus type 6a
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US6143548A (en) * 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)

Also Published As

Publication number Publication date
SI1105466T1 (sl) 2006-08-31
EA200100236A1 (ru) 2001-08-27
PT1105466E (pt) 2006-07-31
ATE324436T1 (de) 2006-05-15
CN1354787A (zh) 2002-06-19
HUP0103091A3 (en) 2002-03-28
EP1105466A4 (en) 2002-05-15
DK1105466T3 (da) 2006-08-14
NZ509610A (en) 2002-10-25
EP1105466A1 (en) 2001-06-13
CA2339034A1 (en) 2000-02-24
WO2000009671A1 (en) 2000-02-24
US6602697B1 (en) 2003-08-05
DE69931053T2 (de) 2006-11-23
AU5469899A (en) 2000-03-06
EP1105466B1 (en) 2006-04-26
ES2262333T3 (es) 2006-11-16
SK2232001A3 (en) 2001-08-06
HUP0103091A2 (hu) 2001-12-28
PL347472A1 (en) 2002-04-08
HRP20010113A2 (en) 2002-02-28
KR20010072470A (ko) 2001-07-31
CA2339034C (en) 2010-10-12
CZ2001570A3 (cs) 2001-09-12
DE69931053D1 (de) 2006-06-01
IL141130A0 (en) 2002-02-10
JP4440471B2 (ja) 2010-03-24
AU760633B2 (en) 2003-05-22
CY1105084T1 (el) 2009-11-04
JP2003520188A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
BR9913026A (pt) Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
FR11C0022I1 (pt)
NL300324I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
DE60029195D1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
DE69535018D1 (de) Papillomavirus vakzine
LU91314I9 (pt)
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
WO2004000220A3 (en) Methods for purifying viral particles for gene therapy
AU6941287A (en) Vaccines for human respiratory virus
EP0816374A3 (en) A method of preparing a composition containing a high proportion of ganglioside
BR0003392A (pt) Processo para produzir xilitol de alta pureza
MXPA03007992A (es) Composicion farmaceutica de fragmentos f(ab)2 de anticuerpos y un proceso para su preparacion
DE59814240D1 (de) Hyaluronidase enthaltendes Präparat und pharmazeutische Verwendung davon
HUP0100132A2 (hu) A béta-lipotropin és felhasználása
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
AU2001287739A1 (en) Process for the purification of epi-hne proteins

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]